Pitavastatin - pharmacological profile from early phase studies

Area of Science:

• Pharmacology
• Cardiovascular Medicine

Background:

• Pitavastatin is a synthetic HMG-CoA reductase inhibitor with a unique cyclopropyl moiety.
• It exhibits distinct properties compared to other statin medications.

Purpose of the Study:

• To investigate the safety, tolerability, and pharmacokinetics of pitavastatin and its metabolite, pitavastatin lactone.
• To compare pitavastatin's efficacy and interaction profile with other statins.

Main Methods:

• Evaluation of pitavastatin's effects on cholesterol synthesis and lipoprotein lipase expression.
• Assessment of safety, tolerability, and pharmacokinetic profiles in diverse patient groups.
• Investigation of metabolic pathways, including cytochrome P450 (CYP) and P-glycoprotein interactions.
• Analysis of drug-food and drug-drug interactions, including with OATP1B1 inhibitors and ciclosporin.

Main Results:

• Pitavastatin demonstrates effective cholesterol synthesis inhibition and increased lipoprotein lipase expression at lower doses.
• It significantly elevates high-density lipoprotein-cholesterol and apolipoprotein A1 levels persistently.
• The drug exhibits high bioavailability (60%), undergoes minimal metabolism (CYP2C9 only), and has limited drug interactions.
• Dosage adjustments are not necessary for age, gender, or race, and it is well-tolerated in healthy subjects.

Conclusions:

• Pitavastatin offers a favorable safety and pharmacokinetic profile with convenient dosing.
• Its minimal drug-drug and drug-food interactions make it suitable for patients requiring multidrug therapy for dyslipidemia.